Eli Lilly and Company at TIDES Europe 2026
Nov 3–5, 2026 Amsterdam, Netherlands ~900 attendees Website
Eli Lilly and Company takes part in 4 sessions at TIDES Europe 2026 in Amsterdam. Its program centres on manufacturing at scale, from next-generation platforms for high-volume oligonucleotides to the CMC behind tirzepatide and the triple receptor agonist retatrutide. It also treats cycle time as a quality metric in taking eloralintide from discovery to clinical proof of concept.
| Organization | TIDES Europe 2026 Attendance |
|---|---|
Eli Lilly and Company Indianapolis, IN | |
Global pharmaceutical company whose peptide medicines include tirzepatide, with programs in oligonucleotide therapeutics. | Keynote Tue Nov 3 13:15–13:50 Making Oligonucleotides a High-Volume Reality: Next-Gen Platforms and Strategy for Oligonucleotide Manufacturing OligonucleotidesCMC & Manufacturing Keynote Tue Nov 3 14:25–15:00 Retatrutide: From Breakthrough Science to Global Medicine — The CMC Story Behind a Novel GIP, GLP-1, and Glucagon Receptor Agonist How the obesity and diabetes drug retatrutide is made at world supply scale by joining peptide fragments in solution with far less waste. PeptidesCMC & Manufacturing Talk Wed Nov 4 16:45–17:15 Made to Scale: What Tirzepatide's Manufacturing Challenge Teaches Us About Innovation Under Pressure Lessons from scaling up production of the diabetes and obesity drug tirzepatide, from an odd result at the bench to tonnes of material. Talk Thu Nov 5 16:00–16:30 Cycle Time Is a Quality Metric: Eloralintide from Discovery to Clinical Proof of Concept How the peptide eloralintide moved from discovery into patients by overlapping chemistry and biology cycles instead of running them one after another. |
Instantly find 20 buyers from Eli Lilly and Company
Get a list of who you should contact, their contact info, and what to say.
Totally free and instant, no sign up necessary!
Not affiliated with or endorsed by Informa Connect or TIDES Europe. Submit a correction